NASDAQ:HALO
Halozyme Therapeutics Stock News
$43.82
-0.100 (-0.228%)
At Close: May 24, 2024
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates
10:25pm, Tuesday, 22'nd Feb 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M
09:05pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
Halozyme Therapeutics press release (HALO): Q4 Non-GAAP EPS of $0.42 beats by $0.01.Revenue of $102M (-16.2% Y/Y) beats by $2.31M.2022 Revenue Guidance of $530 to $560
Halozyme Therapeutics, Inc.'s (HALO) CEO Helen Torley on Q4 2021 Results - Earnings Call Transcript
08:20pm, Tuesday, 22'nd Feb 2022
Halozyme Therapeutics, Inc.'s (HALO) CEO Helen Torley on Q4 2021 Results - Earnings Call Transcript
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates
06:28pm, Tuesday, 22'nd Feb 2022
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Struggling Biotech Name to Report Earnings After the Close
02:34pm, Tuesday, 22'nd Feb 2022
Halozyme Therapeutics Inc (NASDAQ:HALO) is gearing up for its fourth-quarter earnings report, due out after the close today, in which the company is expected to post profits of 41 cents per share.
Halozyme Therapeutics Q4 2021 Earnings Preview
10:35pm, Monday, 21'st Feb 2022 Seeking Alpha
Halozyme Therapeutics (NASDAQ:HALO) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is $0.41 and the consensus
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug A
Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
08:01pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme appoints CFO from within ranks
09:50pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Halozyme Therapeutics (HALO) promoted Nicole LaBrosse to the position of senior vice president and CFO, effective immediately.LaBrosse will succeed Elaine Sun, who is stepping
New Strong Sell Stocks for January 13th
02:15pm, Thursday, 13'th Jan 2022 Zacks Investment Research
CP, HALO, AMX, ESTA, and GEO have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2021.
New Strong Sell Stocks for January 13th
10:46am, Thursday, 13'th Jan 2022
CP, HALO, AMX, ESTA, and GEO have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2021.
Halozyme Therapeutics (HALO) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
08:56pm, Wednesday, 12'th Jan 2022 Seeking Alpha
Halozyme Therapeutics Issues 2022 Guidance; Projects Revenue Growth Of 23-26%
01:49pm, Monday, 10'th Jan 2022 Business Insider Markets
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) said it expects fiscal 2022 non-GAAP earnings per share to be $2.05 to $2.20. For 2022, the company expects GAAP earnings per share of $1.90 to $2.05. For 2022, Halozyme expects GAAP net income of $270 million to $295 million and non-GAAP net income of $290 million to $315 million. For 2022,…
2 Game-Changing Stocks to Invest $1,000 in Right Now
11:15am, Wednesday, 22'nd Dec 2021 The Motley Fool
Do not miss out on these two fundamentally strong stocks.
2 Game-Changing Stocks to Invest $1,000 in Right Now
06:15am, Wednesday, 22'nd Dec 2021
Do not miss out on these two fundamentally strong stocks.
